Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objectives</h3><p>This study aimed to explore the novel biomarkers for immune checkpoint inhibitor (ICI) responses in non‐small cell lung cancer (NSCLC) by integrating genomic profiling, tumor mutational burden (TMB), and expression of programmed death receptor 1 ligand (PD‐L1).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Materials and Methods</h3><p>Tumor and blood samples from 637 Chinese patients with NSCLC were collected for targeted panel sequencing. Genomic alterations, including single nucleotide variations, insertions/deletions, copy number variations, and gene rearrangements, were assessed and TMB was computed. TMB‐high (TMB‐H) was defined as ≥10 mutations/Mb. PD‐L1 positivity was defined as ≥1% tumor cells with membranous staining. Genomic data and ICI outcomes of 240 patients with NSCLC were derived from cBioPortal.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p><i>EGFR</i>‐sensitizing mutations, <i>ALK</i>, <i>RET</i>, and <i>ROS1</i> rearrangements were associated with lower TMB and PD‐L1+/TMB‐H proportions, whereas <i>KRAS</i>, <i>ALK</i>, <i>RET</i>, and <i>ROS1</i> substitutions/indels correlated with higher TMB and PD‐L1+/TMB‐H proportions than wild‐type genotypes. Histone‐lysine N‐methyltransferase 2 (<i>KMT2</i>) family members (<i>KMT2A</i>, <i>KMT2C</i>, and <i>KMT2D</i>) were frequently mutated in NSCLC tumors, and these mutations were associated with higher TMB and PD‐L1 expression, as well as higher PD‐L1+/TMB‐H proportions. Specifically, patients with KMT2C mutations had higher TMB and PD‐L1+/TMB‐H proportions than wild‐type patients. The median progression‐free survival (PFS) was 5.47 months (95% CI 2.5–NA) in patients with KMT2C mutations versus 3.17 months (95% CI 2.6–4.27) in wild‐type patients (<i>p</i> = 0.058). Furthermore, in patients with NSCLC who underwent ICI treatment, patients with TP53/KMT2C co‐mutations had significantly longer PFS and greater durable clinical benefit (HR: 0.48, 95% CI: 0.24–0.94, <i>p</i> = 0.033). TP53 mutation combined with KMT2C or KRAS mutation was a better biomarker with expanded population benefit from ICIs therapy and increased the predictive power (HR: 0.46, 95% CI: 0.26–0.81, <i>p</i> = 0.007). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>We found that tumors with different alterations in actionable target genes had variable expression of PD‐L1 and TMB in NSCLC. TP53/KMT2C co‐mutation might serve as a predictive biomarker for ICI responses in NSCLC.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Implications for Practice</h3><p>Cancer immunotherapies, especially immune checkpoint inhibitors (ICIs), have revolutionized the treatment of non‐small cell lung cancer (NSCLC); however, only a proportion of patients derive durable responses to this treatment. Biomarkers with greater accuracy are highly needed. In total, 637 Chinese patients with NSCLC were analyzed using next‐generation sequencing and IHC to characterize the unique features of genomic alterations and TMB and PD‐L1 expression. Our study demonstrated that KMT2C/TP53 co‐mutation might be an accurate, cost‐effective, and reliable biomarker to predict responses to PD‐1 blockade therapy in NSCLC patients and that adding KRAS to the biomarker combination creates a more robust parameter to identify the best responders to ICI therapy.</p></section>

The Immune Response-Related Mutational Signatures and Driver Genes in Non-Small-cell Lung Cancer

Identification of Immune-Related Gene Signature for Non-Small Cell Lung Cancer Patients with Immune Checkpoint Inhibitors

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

A New Immune Signature for Survival Prediction and Immune Checkpoint Molecules in Non-Small Cell Lung Cancer

Identification of Nomogram Associated with Durable Clinical Benefit Gene for Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Immunotherapy

A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients

Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung cancer

The Emerging Development of Tumor Mutational Burden in Patients with NSCLC.

Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-Pd-(l)1 Therapies in NSCLC.

The emerging development of tumor mutational burden in patients with NSCLC

Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer

A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

Prediction Performance Comparison of Biomarkers for Response to Immune Checkpoint Inhibitors in Advanced Non‐small Cell Lung Cancer

Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer

Biomarkers of response to immunotherapy in early stage non-small cell lung cancer

Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Co-Occurring Alteration of NOTCH and DDR Pathways Serves as Novel Predictor to Efficacious Immunotherapy in NSCLC

Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma

Relationship Between the Efficacy of Immunotherapy and Characteristics of Specific Tumor Mutation Genes in Non‐small Cell Lung Cancer Patients